BNT162b2 vaccination induces durable SARS-CoV-2–specific T cells with a stem cell memory phenotype
Gisella Guerrera, Mario Picozza, Silvia D’Orso, Roberta Placido, Marta Pirronello, Alice Verdiani, Andrea Termine, Carlo Fabrizio, Flavia Giannessi, Manolo Sambucci, Maria Pia Balice, Carlo Caltagirone, Antonino Salvia, Angelo Rossini, Luca Battistini, Giovanna Borsellino
Abstract
T cell response. These cells appeared before the development of high antibody titers, displayed markers of immunological maturity and stem cell memory, survived the physiological contraction of the immune response, and persisted for at least 6 months. Collectively, these data show that vaccination with BNT162b2 elicits an immunologically competent and long-lived SARS-CoV-2–specific T cell population.
Topics & Concepts
PhenotypeStem cellVaccinationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BiologyCoronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakImmunologyMedicineCell biologyGeneticsGeneDiseaseOutbreakPathologyInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmune responses and vaccinations